Rani Therapeutics Holdings Inc Cl A (RANI)

$0.83 +0.03 (4.28%)
Market Cap 98.60M
Revenue (ttm) 1.63M
Net Income (ttm) -29.67M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -1,820.25%
Debt to Equity Ratio 0.00
Volume 2,632,100
Avg Vol 835,500
Day's Range N/A - N/A
Shares Out 123.88M
Stochastic %K 53%
Beta 0.78
Analysts Strong Sell
Price Target $7.40

Company Profile

Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company, focusing on technologies to enable the administration of biologics and drugs orally for patients, physicians, and healthcare systems with a alternative to painful injections in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes...

Industry: Biotechnology
Sector: Healthcare
Phone: 408 457 3700
Address:
2051 Ringwood Avenue, San Jose, United States
Makingmillions192
Makingmillions192 Aug. 19 at 12:18 PM
$LEXX Ngl I was fearful we might have seen a raise yesterday or today - there is a phrase in biotech. Raise when you can not when you have to. And to see the team not crush this momentum but rather stare human study #7 directly in the eye I’ve got to say it’s incredibly BULLISH. Obviously they know MUCH more than us about what’s happening on the business development side. But I just want to say that it’s very bullish that they haven’t raised on this momentum. Now, short term technicals are incredibly overbought - however it’s been driven by the MTA with PegBio so it makes sense.. this has been a value re-rate so far, it’s clear as day. What happens from here is anyone’s guess but it looks like consolidation / the uptrend phase will continue and CLEARLY both mgmt and the market is bullish on what’s to come. Exciting times 🔥 $LLY $RANI $NVO $NVO
0 · Reply
Mandalo
Mandalo Aug. 19 at 5:44 AM
$RANI TIMELINE AND KEY PRICE CATALYSTS ​Late 2026 – Phase 1a Expansion (RT-114): Topline data from 15 additional subjects receiving double-dose (24 mg total) RaniPills. ​Late 2026 – Phase 1b Initiation (RT-114): Start of the 8-week repeat-dose study in patients with overweight or obesity. ​1H 2027 – Phase 1b Readout (RT-114): Critical data on oral GLP-1/GLP-2 efficacy, safety, and weight loss. ​Platform & Partnerships: Potential milestone announcements or target opt-ins from Chugai Pharmaceutical (up to 5 additional targets) and PegBio, as well as potential new licensing deals. ​Financial Runway: $53.4M in cash/equivalents (Q2 2026) funds operations through late 2027.
0 · Reply
Sirsquiggleburp
Sirsquiggleburp Aug. 18 at 9:37 PM
$RANI Looking at this for a swing.
0 · Reply
Fishbonee
Fishbonee Aug. 18 at 9:16 PM
$RANI 📈
0 · Reply
wavw
wavw Aug. 18 at 8:13 PM
$RANI closing above .80 is positive
0 · Reply
wavw
wavw Aug. 18 at 5:33 PM
$RANI back to below .80. Some tutes are buying …now 46.5%
0 · Reply
Makingmillions192
Makingmillions192 Aug. 18 at 4:55 PM
$LEXX Rani ran to a 250m mkt cap on their deal at the end of 2025. Not out of the question to say we can 10x from here if the existing MTA partner structures something similar. Very exciting 💰 $RANI $LLY $VKTX $NVO
0 · Reply
wavw
wavw Aug. 18 at 3:33 PM
$RANI Atleast worth of $1 definitely.
0 · Reply
BinaryLogic
BinaryLogic Aug. 18 at 2:43 PM
$RANI [Again] I have been consistent here - DCA into your position $0.7-0.8 ideally with multiplier upside on RT-114 progress, broader commercialization of the RaniPill. The global biologics industry is more than $50T, and RANI has technology/IP where (if proven) could result in broad commercialization of oral therapeutics.
0 · Reply
KaShing01
KaShing01 Aug. 18 at 2:03 PM
$RANI $8+ https://www.marketbeat.com/instant-alerts/chardan-capital-initiates-coverage-on-rani-therapeutics-nasdaqrani-2026-08-18/
0 · Reply
Latest News on RANI
Rani Therapeutics initiated with a Buy at Chardan

2026-08-18T11:10:37.000Z - 1 day ago

Rani Therapeutics initiated with a Buy at Chardan

Rani Therapeutics reports Q2 EPS (4c), consensus (5c)

2026-08-16T14:06:16.000Z - 2 days ago

Rani Therapeutics reports Q2 EPS (4c), consensus (5c)

Rani Therapeutics Reports Second Quarter 2026 Financial Results; Provides Corporate Update

Aug 13, 2026, 4:05 PM EDT - 5 days ago

Rani Therapeutics Reports Second Quarter 2026 Financial Results; Provides Corporate Update

Rani Therapeutics Holdings Earnings release: Q2 2026

Aug 13, 2026, 4:00 PM EDT - 5 days ago

Rani Therapeutics Holdings Earnings release: Q2 2026

Rani Therapeutics Holdings Quarterly report: Q2 2026

Aug 13, 2026, 4:00 PM EDT - 5 days ago

Rani Therapeutics Holdings Quarterly report: Q2 2026

Rani Therapeutics Holdings Transcript: Canaccord Genuity's 46th Annual Growth Conference

Aug 12, 2026, 2:30 PM EDT - 6 days ago

Rani Therapeutics Holdings Transcript: Canaccord Genuity's 46th Annual Growth Conference

Rani Therapeutics to Participate in the Canaccord Genuity 46th Annual Growth Conference

Aug 10, 2026, 8:00 AM EDT - 9 days ago

Rani Therapeutics to Participate in the Canaccord Genuity 46th Annual Growth Conference

Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Jul 20, 2026, 4:05 PM EDT - 4 weeks ago

Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Rani Therapeutics reports initial data from RT-114 study

2026-07-15T12:40:48.000Z - 4 weeks ago

Rani Therapeutics reports initial data from RT-114 study

Rani Therapeutics Announces Positive Initial Phase 1a Data for RT-114 for the Treatment of Obesity, with Oral Bioavailability Exceeding Matched Subcutaneous Dosing

Jul 15, 2026, 8:00 AM EDT - 5 weeks ago

Rani Therapeutics Announces Positive Initial Phase 1a Data for RT-114 for the Treatment of Obesity, with Oral Bioavailability Exceeding Matched Subcutaneous Dosing

Rani Therapeutics announces research, development collaboration with PegBio

2026-07-09T20:15:21.000Z - 5 weeks ago

Rani Therapeutics announces research, development collaboration with PegBio

Rani Therapeutics Announces Research and Development Collaboration with PegBio to Expand Obesity Pipeline Across Multiple Novel Candidates

Jul 9, 2026, 4:05 PM EDT - 5 weeks ago

Rani Therapeutics Announces Research and Development Collaboration with PegBio to Expand Obesity Pipeline Across Multiple Novel Candidates

Rani Therapeutics appoints Nicholas Maestas as CFO

2026-06-29T12:20:41.000Z - 7 weeks ago

Rani Therapeutics appoints Nicholas Maestas as CFO

TPST

Rani Therapeutics Appoints Nicholas Maestas as Chief Financial Officer

Jun 29, 2026, 8:00 AM EDT - 7 weeks ago

Rani Therapeutics Appoints Nicholas Maestas as Chief Financial Officer

Rani Therapeutics Holdings Transcript: AGM 2026

May 28, 2026, 11:00 AM EDT - 2 months ago

Rani Therapeutics Holdings Transcript: AGM 2026

Rani Therapeutics Holdings, Inc. Announces Pricing of $20.0 Million Registered Direct Offering of Class A Common Stock Priced At-The-Market Under Nasdaq Rules

May 26, 2026, 8:00 AM EDT - 3 months ago

Rani Therapeutics Holdings, Inc. Announces Pricing of $20.0 Million Registered Direct Offering of Class A Common Stock Priced At-The-Market Under Nasdaq Rules

Rani Therapeutics Reports First Quarter 2026 Financial Results; Provides Corporate Update; Announces CFO Transition

May 15, 2026, 4:05 PM EDT - 3 months ago

Rani Therapeutics Reports First Quarter 2026 Financial Results; Provides Corporate Update; Announces CFO Transition

Rani Therapeutics Holdings Quarterly report: Q1 2026

May 15, 2026, 7:00 AM EDT - 3 months ago

Rani Therapeutics Holdings Quarterly report: Q1 2026

Rani Therapeutics Holdings Earnings release: Q1 2026

May 15, 2026, 7:00 AM EDT - 3 months ago

Rani Therapeutics Holdings Earnings release: Q1 2026

Rani Therapeutics to Participate in the H.C. Wainwright Annual BioConnect Investor Conference

May 12, 2026, 4:05 PM EDT - 3 months ago

Rani Therapeutics to Participate in the H.C. Wainwright Annual BioConnect Investor Conference

Rani Therapeutics Holdings Proxy statement: Proxy filing

Apr 16, 2026, 8:00 AM EDT - 4 months ago

Rani Therapeutics Holdings Proxy statement: Proxy filing

Rani Therapeutics Holdings Proxy statement: Proxy filing

Apr 16, 2026, 8:00 AM EDT - 4 months ago

Rani Therapeutics Holdings Proxy statement: Proxy filing

Rani Therapeutics Appoints Dr. Sara Kenkare-Mitra as Strategic Advisor to Advance Platform and Clinical Strategy

Apr 9, 2026, 7:00 AM EDT - 4 months ago

Rani Therapeutics Appoints Dr. Sara Kenkare-Mitra as Strategic Advisor to Advance Platform and Clinical Strategy

Rani Therapeutics price target lowered to $5 from $9 at Canaccord

2026-04-01T11:31:50.000Z - 5 months ago

Rani Therapeutics price target lowered to $5 from $9 at Canaccord

Rani Therapeutics Holdings Earnings Call Transcript: Q4 2025

Mar 26, 2026, 4:30 PM EDT - 5 months ago

Rani Therapeutics Holdings Earnings Call Transcript: Q4 2025

Rani Therapeutics Holdings Annual report: Q4 2025

Mar 26, 2026, 4:30 PM EDT - 5 months ago

Rani Therapeutics Holdings Annual report: Q4 2025

Rani Therapeutics Holdings Earnings release: Q4 2025

Mar 26, 2026, 4:30 PM EDT - 5 months ago

Rani Therapeutics Holdings Earnings release: Q4 2025

Rani Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results; Provides Corporate Update

Mar 26, 2026, 4:05 PM EDT - 5 months ago

Rani Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results; Provides Corporate Update

Rani Therapeutics Appoints Jesper Høiland as Head of Strategy to Advance Corporate and Pipeline Prioritization

Mar 25, 2026, 4:53 PM EDT - 5 months ago

Rani Therapeutics Appoints Jesper Høiland as Head of Strategy to Advance Corporate and Pipeline Prioritization

Rani Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results

Mar 19, 2026, 4:05 PM EDT - 5 months ago

Rani Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results

Rani Therapeutics promotes Javadi to Chief Technical Officer

2026-01-28T12:15:42.000Z - 7 months ago

Rani Therapeutics promotes Javadi to Chief Technical Officer

Rani Therapeutics Announces the Promotion of Alireza Javadi, Ph.D. to Chief Technical Officer

Jan 28, 2026, 7:00 AM EST - 7 months ago

Rani Therapeutics Announces the Promotion of Alireza Javadi, Ph.D. to Chief Technical Officer

Rani Therapeutics initiates Phase 1 study of RT-114 RaniPill

2026-01-08T12:10:14.000Z - 7 months ago

Rani Therapeutics initiates Phase 1 study of RT-114 RaniPill

Rani Therapeutics Initiates Phase 1 Study of RT-114 RaniPill® for the Treatment of Obesity in Collaboration with ProGen

Jan 8, 2026, 7:00 AM EST - 7 months ago

Rani Therapeutics Initiates Phase 1 Study of RT-114 RaniPill® for the Treatment of Obesity in Collaboration with ProGen

Rani Therapeutics to Participate in the Evercore Healthcare Conference

Nov 24, 2025, 4:05 PM EST - 9 months ago

Rani Therapeutics to Participate in the Evercore Healthcare Conference

Rani Therapeutics files to sell 42.63M shares of Class A common stock for holder

2025-11-07T22:15:16.000Z - 10 months ago

Rani Therapeutics files to sell 42.63M shares of Class A common stock for holder

Rani Therapeutics Holdings Registration statement: Registration Filing

Nov 7, 2025, 7:00 AM EST - 10 months ago

Rani Therapeutics Holdings Registration statement: Registration Filing

Rani Therapeutics Reports Third Quarter 2025 Financial Results; Provides Corporate Update

Nov 6, 2025, 4:30 PM EST - 10 months ago

Rani Therapeutics Reports Third Quarter 2025 Financial Results; Provides Corporate Update

Rani Therapeutics Holdings Earnings release: Q3 2025

Nov 6, 2025, 7:00 AM EST - 10 months ago

Rani Therapeutics Holdings Earnings release: Q3 2025

Rani Therapeutics Holdings Quarterly report: Q3 2025

Nov 6, 2025, 7:00 AM EST - 10 months ago

Rani Therapeutics Holdings Quarterly report: Q3 2025

Rani Therapeutics to Present Preclinical Data on Oral Delivery of Semaglutide via the RaniPill® Capsule at ObesityWeek® 2025

Oct 30, 2025, 8:00 AM EDT - 10 months ago

Rani Therapeutics to Present Preclinical Data on Oral Delivery of Semaglutide via the RaniPill® Capsule at ObesityWeek® 2025

Rani Therapeutics Announces the Appointments of Abe Bassan and Vasudev Bailey, Ph.D. to Board of Directors

Oct 23, 2025, 4:05 PM EDT - 10 months ago

Rani Therapeutics Announces the Appointments of Abe Bassan and Vasudev Bailey, Ph.D. to Board of Directors

Rani Therapeutics Announces Closing of Oversubscribed $60.3 Million Private Placement Priced At-the-Market under Nasdaq Rules

Oct 23, 2025, 4:01 PM EDT - 10 months ago

Rani Therapeutics Announces Closing of Oversubscribed $60.3 Million Private Placement Priced At-the-Market under Nasdaq Rules

CRMD, RANI, CELC, RAPT: four biotech stocks flying high today and why

Oct 20, 2025, 9:42 AM EDT - 10 months ago

CRMD, RANI, CELC, RAPT: four biotech stocks flying high today and why

CELC CRMD RAPT

Rani Therapeutics signs up to $1.09 billion licensing deal with Japan's Chugai Pharma

Oct 17, 2025, 7:48 AM EDT - 10 months ago

Rani Therapeutics signs up to $1.09 billion licensing deal with Japan's Chugai Pharma

Rani Therapeutics Announces Oversubscribed $60.3 Million Private Placement Priced At-the-Market under Nasdaq Rules

Oct 17, 2025, 7:31 AM EDT - 10 months ago

Rani Therapeutics Announces Oversubscribed $60.3 Million Private Placement Priced At-the-Market under Nasdaq Rules

Rani Therapeutics Announces up to $1.085 Billion Collaboration with Chugai Pharmaceutical Co. for Multiple High-Value Therapeutics Including Rare Disease and Immunology Programs and Announces Concurrent Oversubscribed $60.3 Million Financing

Oct 17, 2025, 7:30 AM EDT - 10 months ago

Rani Therapeutics Announces up to $1.085 Billion Collaboration with Chugai Pharmaceutical Co. for Multiple High-Value Therapeutics Including Rare Disease and Immunology Programs and Announces Concurrent Oversubscribed $60.3 Million Financing

Rani Therapeutics Holdings Registration statement: Registration Filing

Aug 8, 2025, 8:00 AM EDT - 1 year ago

Rani Therapeutics Holdings Registration statement: Registration Filing

Rani Therapeutics Reports Second Quarter 2025 Financial Results; Provides Corporate Update

Aug 7, 2025, 4:05 PM EDT - 1 year ago

Rani Therapeutics Reports Second Quarter 2025 Financial Results; Provides Corporate Update

Rani Therapeutics Holdings Earnings release: Q2 2025

Aug 7, 2025, 4:00 PM EDT - 1 year ago

Rani Therapeutics Holdings Earnings release: Q2 2025

Rani Therapeutics Holdings Quarterly report: Q2 2025

Aug 7, 2025, 4:00 PM EDT - 1 year ago

Rani Therapeutics Holdings Quarterly report: Q2 2025

Rani Therapeutics Holdings, Inc. Announces Pricing of $3.0 Million Registered Direct Offering

Jul 15, 2025, 9:00 AM EDT - 1 year ago

Rani Therapeutics Holdings, Inc. Announces Pricing of $3.0 Million Registered Direct Offering

Rani Therapeutics and ProGen Announce Late Breaking Presentation at ENDO 2025 Demonstrating Bioequivalence of Novel, Bispecific GLP-1/GLP-2 Receptor Agonist Delivered Orally via RaniPill Compared to Subcutaneous Delivery

Jul 14, 2025, 5:00 AM EDT - 1 year ago

Rani Therapeutics and ProGen Announce Late Breaking Presentation at ENDO 2025 Demonstrating Bioequivalence of Novel, Bispecific GLP-1/GLP-2 Receptor Agonist Delivered Orally via RaniPill Compared to Subcutaneous Delivery

Rani Therapeutics Holdings Registration statement: Registration Filing

Jul 3, 2025, 8:00 AM EDT - 1 year ago

Rani Therapeutics Holdings Registration statement: Registration Filing

Rani Therapeutics Announces Research Agreement with Chugai

May 19, 2025, 8:00 AM EDT - 1 year ago

Rani Therapeutics Announces Research Agreement with Chugai

Rani Therapeutics Reports First Quarter 2025 Financial Results; Provides Corporate Update

May 13, 2025, 4:05 PM EDT - 1 year ago

Rani Therapeutics Reports First Quarter 2025 Financial Results; Provides Corporate Update

Rani Therapeutics Holdings Quarterly report: Q1 2025

May 13, 2025, 9:30 AM EDT - 1 year ago

Rani Therapeutics Holdings Quarterly report: Q1 2025

Rani Therapeutics Holdings Earnings release: Q1 2025

May 13, 2025, 9:30 AM EDT - 1 year ago

Rani Therapeutics Holdings Earnings release: Q1 2025

Rani Therapeutics Holdings Proxy statement: Proxy Filing

Apr 30, 2025, 8:00 AM EDT - 1 year ago

Rani Therapeutics Holdings Proxy statement: Proxy Filing

Rani Therapeutics Holdings Proxy statement: Proxy Filing

Apr 16, 2025, 8:00 AM EDT - 1 year ago

Rani Therapeutics Holdings Proxy statement: Proxy Filing

Rani Therapeutics Holdings Proxy statement: Proxy Filing

Apr 16, 2025, 8:00 AM EDT - 1 year ago

Rani Therapeutics Holdings Proxy statement: Proxy Filing

Rani Therapeutics Holdings Earnings Call Transcript: Q4 2024

Mar 31, 2025, 4:30 PM EDT - 1 year ago

Rani Therapeutics Holdings Earnings Call Transcript: Q4 2024

Rani Therapeutics Holdings Annual report: Q4 2024

Mar 31, 2025, 4:30 PM EDT - 1 year ago

Rani Therapeutics Holdings Annual report: Q4 2024

Rani Therapeutics Holdings Earnings release: Q4 2024

Mar 31, 2025, 4:30 PM EDT - 1 year ago

Rani Therapeutics Holdings Earnings release: Q4 2024

Rani Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results; Provides Corporate Update

Mar 31, 2025, 4:05 PM EDT - 1 year ago

Rani Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results; Provides Corporate Update

Rani Therapeutics Announces Preclinical Data Demonstrating Bioequivalence of RT-114, a GLP-1/GLP-2 Dual Agonist (PG-102) Delivered Orally via the RaniPill® Capsule, to Subcutaneously Administered PG-102

Mar 26, 2025, 4:05 PM EDT - 1 year ago

Rani Therapeutics Announces Preclinical Data Demonstrating Bioequivalence of RT-114, a GLP-1/GLP-2 Dual Agonist (PG-102) Delivered Orally via the RaniPill® Capsule, to Subcutaneously Administered PG-102

Rani Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results

Mar 25, 2025, 6:00 PM EDT - 1 year ago

Rani Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results

Rani Therapeutics Holdings Transcript: 7th Annual Evercore ISI HealthCONx Conference

Dec 4, 2024, 12:55 PM EST - 1 year ago

Rani Therapeutics Holdings Transcript: 7th Annual Evercore ISI HealthCONx Conference

Rani Therapeutics Holdings Transcript: Stifel 2024 Healthcare Conference

Nov 18, 2024, 4:10 PM EST - 1 year ago

Rani Therapeutics Holdings Transcript: Stifel 2024 Healthcare Conference

Rani Therapeutics Holdings Transcript: UBS Global Healthcare Conference 2024

Nov 14, 2024, 1:15 PM EST - 1 year ago

Rani Therapeutics Holdings Transcript: UBS Global Healthcare Conference 2024

Rani Therapeutics Holdings Quarterly report: Q3 2024

Nov 14, 2024, 8:00 AM EST - 1 year ago

Rani Therapeutics Holdings Quarterly report: Q3 2024

Rani Therapeutics Holdings Earnings release: Q3 2024

Nov 14, 2024, 8:00 AM EST - 1 year ago

Rani Therapeutics Holdings Earnings release: Q3 2024

Rani Therapeutics Holdings, Inc. Announces Pricing of $10.0 Million Registered Direct Offering and Cancellation of Certain Existing Warrants

Oct 15, 2024, 8:30 AM EDT - 2 years ago

Rani Therapeutics Holdings, Inc. Announces Pricing of $10.0 Million Registered Direct Offering and Cancellation of Certain Existing Warrants

Rani Therapeutics to Participate in the 2024 Maxim Healthcare Virtual Summit

Oct 8, 2024, 4:05 PM EDT - 2 years ago

Rani Therapeutics to Participate in the 2024 Maxim Healthcare Virtual Summit

Rani Therapeutics Holdings Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

Sep 18, 2024, 11:30 AM EDT - 2 years ago

Rani Therapeutics Holdings Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

Rani Therapeutics to Participate in September Investor Conferences

Sep 3, 2024, 4:05 PM EDT - 2 years ago

Rani Therapeutics to Participate in September Investor Conferences

Rani Therapeutics Holdings Transcript: Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase 2024

Aug 13, 2024, 3:30 PM EDT - 2 years ago

Rani Therapeutics Holdings Transcript: Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase 2024

Rani Therapeutics Reports Second Quarter 2024 Financial Results; Provides Corporate Update

Aug 6, 2024, 4:05 PM EDT - 2 years ago

Rani Therapeutics Reports Second Quarter 2024 Financial Results; Provides Corporate Update

Rani Therapeutics Holdings Quarterly report: Q2 2024

Aug 6, 2024, 6:00 AM EDT - 2 years ago

Rani Therapeutics Holdings Quarterly report: Q2 2024

Rani Therapeutics Holdings Earnings release: Q2 2024

Aug 6, 2024, 6:00 AM EDT - 2 years ago

Rani Therapeutics Holdings Earnings release: Q2 2024

Rani Therapeutics to Participate in August Investor Conferences

Jul 29, 2024, 4:05 PM EDT - 2 years ago

Rani Therapeutics to Participate in August Investor Conferences

Rani Therapeutics Holdings, Inc. Announces Pricing of $10.0 Million Registered Direct Offering

Jul 22, 2024, 8:30 AM EDT - 2 years ago

Rani Therapeutics Holdings, Inc. Announces Pricing of $10.0 Million Registered Direct Offering

Rani Therapeutics Holdings Transcript: Investor Update

Jun 24, 2024, 8:00 AM EDT - 2 years ago

Rani Therapeutics Holdings Transcript: Investor Update

Rani Therapeutics Holdings Press release: Investor Update

Jun 24, 2024, 8:00 AM EDT - 2 years ago

Rani Therapeutics Holdings Press release: Investor Update

Rani Therapeutics Holdings Slides: Investor Update

Jun 24, 2024, 8:00 AM EDT - 2 years ago

Rani Therapeutics Holdings Slides: Investor Update

Rani Therapeutics Announces Partnership with ProGen on Development of Oral Obesity Treatment

Jun 24, 2024, 7:00 AM EDT - 2 years ago

Rani Therapeutics Announces Partnership with ProGen on Development of Oral Obesity Treatment

Rani Therapeutics Holdings Transcript: H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ

May 20, 2024, 2:30 PM EDT - 2 years ago

Rani Therapeutics Holdings Transcript: H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ

Rani Therapeutics to Participate in May Investor Conferences

May 14, 2024, 8:00 AM EDT - 2 years ago

Rani Therapeutics to Participate in May Investor Conferences

Rani Therapeutics to Present Clinical and Preclinical Data on Oral Delivery of an Ustekinumab Biosimilar via the RaniPill® Capsule at Digestive Disease Week 2024

May 9, 2024, 8:00 AM EDT - 2 years ago

Rani Therapeutics to Present Clinical and Preclinical Data on Oral Delivery of an Ustekinumab Biosimilar via the RaniPill® Capsule at Digestive Disease Week 2024

Rani Therapeutics Reports First Quarter 2024 Financial Results; Provides Corporate Update

May 6, 2024, 4:05 PM EDT - 2 years ago

Rani Therapeutics Reports First Quarter 2024 Financial Results; Provides Corporate Update

Rani Therapeutics Holdings Quarterly report: Q1 2024

May 6, 2024, 7:00 AM EDT - 2 years ago

Rani Therapeutics Holdings Quarterly report: Q1 2024

Rani Therapeutics Holdings Earnings release: Q1 2024

May 6, 2024, 7:00 AM EDT - 2 years ago

Rani Therapeutics Holdings Earnings release: Q1 2024

Rani Therapeutics Holdings Proxy statement: Proxy Filing

Apr 17, 2024, 8:00 AM EDT - 2 years ago

Rani Therapeutics Holdings Proxy statement: Proxy Filing

Rani Therapeutics Holdings Proxy statement: Proxy Filing

Apr 17, 2024, 8:00 AM EDT - 2 years ago

Rani Therapeutics Holdings Proxy statement: Proxy Filing

Rani Therapeutics Holdings Earnings Call Transcript: Q4 2023

Mar 20, 2024, 4:30 PM EDT - 2 years ago

Rani Therapeutics Holdings Earnings Call Transcript: Q4 2023

Rani Therapeutics Holdings Annual report: Q4 2023

Mar 20, 2024, 4:30 PM EDT - 2 years ago

Rani Therapeutics Holdings Annual report: Q4 2023

Rani Therapeutics Holdings Earnings release: Q4 2023

Mar 20, 2024, 4:30 PM EDT - 2 years ago

Rani Therapeutics Holdings Earnings release: Q4 2023

Rani Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results; Provides Corporate Update

Mar 20, 2024, 4:05 PM EDT - 2 years ago

Rani Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results; Provides Corporate Update

Rani Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results

Mar 15, 2024, 4:05 PM EDT - 2 years ago

Rani Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results

Rani Therapeutics Announces Preclinical Pharmacodynamic Data on Transenteric Delivery of GLP-1 Incretin Triagonist

Dec 14, 2023, 8:00 AM EST - 2 years ago

Rani Therapeutics Announces Preclinical Pharmacodynamic Data on Transenteric Delivery of GLP-1 Incretin Triagonist

Rani Therapeutics Reports Third Quarter 2023 Financial Results; Provides Corporate Update

Nov 8, 2023, 4:05 PM EST - 3 years ago

Rani Therapeutics Reports Third Quarter 2023 Financial Results; Provides Corporate Update

Rani Therapeutics Holdings Quarterly report: Q3 2023

Nov 8, 2023, 4:00 PM EST - 3 years ago

Rani Therapeutics Holdings Quarterly report: Q3 2023

Rani Therapeutics Announces Successful Oral Delivery of Monoclonal Antibody via High-Capacity Pill in Preclinical Study

Oct 19, 2023, 4:05 PM EDT - 3 years ago

Rani Therapeutics Announces Successful Oral Delivery of Monoclonal Antibody via High-Capacity Pill in Preclinical Study

Rani Therapeutics to Present Abstract on RT-102 at the 2023 Annual Meeting of the American Society for Bone and Mineral Research

Oct 12, 2023, 4:05 PM EDT - 3 years ago

Rani Therapeutics to Present Abstract on RT-102 at the 2023 Annual Meeting of the American Society for Bone and Mineral Research

Rani Therapeutics Initiates Phase 1 Study of RT-111 (RaniPill® Containing Ustekinumab Biosimilar, CT-P43)

Sep 18, 2023, 8:00 AM EDT - 3 years ago

Rani Therapeutics Initiates Phase 1 Study of RT-111 (RaniPill® Containing Ustekinumab Biosimilar, CT-P43)

Makingmillions192
Makingmillions192 Aug. 19 at 12:18 PM
$LEXX Ngl I was fearful we might have seen a raise yesterday or today - there is a phrase in biotech. Raise when you can not when you have to. And to see the team not crush this momentum but rather stare human study #7 directly in the eye I’ve got to say it’s incredibly BULLISH. Obviously they know MUCH more than us about what’s happening on the business development side. But I just want to say that it’s very bullish that they haven’t raised on this momentum. Now, short term technicals are incredibly overbought - however it’s been driven by the MTA with PegBio so it makes sense.. this has been a value re-rate so far, it’s clear as day. What happens from here is anyone’s guess but it looks like consolidation / the uptrend phase will continue and CLEARLY both mgmt and the market is bullish on what’s to come. Exciting times 🔥 $LLY $RANI $NVO $NVO
0 · Reply
Mandalo
Mandalo Aug. 19 at 5:44 AM
$RANI TIMELINE AND KEY PRICE CATALYSTS ​Late 2026 – Phase 1a Expansion (RT-114): Topline data from 15 additional subjects receiving double-dose (24 mg total) RaniPills. ​Late 2026 – Phase 1b Initiation (RT-114): Start of the 8-week repeat-dose study in patients with overweight or obesity. ​1H 2027 – Phase 1b Readout (RT-114): Critical data on oral GLP-1/GLP-2 efficacy, safety, and weight loss. ​Platform & Partnerships: Potential milestone announcements or target opt-ins from Chugai Pharmaceutical (up to 5 additional targets) and PegBio, as well as potential new licensing deals. ​Financial Runway: $53.4M in cash/equivalents (Q2 2026) funds operations through late 2027.
0 · Reply
Sirsquiggleburp
Sirsquiggleburp Aug. 18 at 9:37 PM
$RANI Looking at this for a swing.
0 · Reply
Fishbonee
Fishbonee Aug. 18 at 9:16 PM
$RANI 📈
0 · Reply
wavw
wavw Aug. 18 at 8:13 PM
$RANI closing above .80 is positive
0 · Reply
wavw
wavw Aug. 18 at 5:33 PM
$RANI back to below .80. Some tutes are buying …now 46.5%
0 · Reply
Makingmillions192
Makingmillions192 Aug. 18 at 4:55 PM
$LEXX Rani ran to a 250m mkt cap on their deal at the end of 2025. Not out of the question to say we can 10x from here if the existing MTA partner structures something similar. Very exciting 💰 $RANI $LLY $VKTX $NVO
0 · Reply
wavw
wavw Aug. 18 at 3:33 PM
$RANI Atleast worth of $1 definitely.
0 · Reply
BinaryLogic
BinaryLogic Aug. 18 at 2:43 PM
$RANI [Again] I have been consistent here - DCA into your position $0.7-0.8 ideally with multiplier upside on RT-114 progress, broader commercialization of the RaniPill. The global biologics industry is more than $50T, and RANI has technology/IP where (if proven) could result in broad commercialization of oral therapeutics.
0 · Reply
KaShing01
KaShing01 Aug. 18 at 2:03 PM
$RANI $8+ https://www.marketbeat.com/instant-alerts/chardan-capital-initiates-coverage-on-rani-therapeutics-nasdaqrani-2026-08-18/
0 · Reply
Mandalo
Mandalo Aug. 18 at 2:03 PM
$RANI Wall Street analysts maintain a consensus Strong Buy / Moderate Buy on $RANI, with an average 12-month price target of ~$7.50–$8.75 (~800%+ upside from current levels around $0.80). ​Recent Analyst Targets: ​HC Wainwright: Buy | $11.00 ​Lake Street: Buy | $9.00 ​Chardan Capital: Buy | $6.00 ​Canaccord Genuity: Buy | $5.00 ​Bull Case: Massive upside potential driven by oral biologics pipeline (RaniPill) and potential pharma partnerships. 🚀 ​Bear Case: High cash-burn biotech risks; quantitative models (like Weiss) rate as Sell (E+) due to micro-cap volatility and dilutive risks. ⚠️
0 · Reply
Carlisle007
Carlisle007 Aug. 18 at 1:40 PM
$RANI nice some action on the open
0 · Reply
Makingmillions192
Makingmillions192 Aug. 18 at 12:12 PM
🔥 $LEXX: NASDAQ CLEAR. NEXT STOP: STUDY #7! 🚀 My worst fear going into today was a cheap offering off the momentum—INSTEAD WE GOT: ✅ Nasdaq Compliance Regained (No delisting overhang! Hearing CANCELLED!) ✅ Zero Cash-Grab Dilution (Management knows what they hold!) ✅ $10+ Breakout Closed Strong ($10.32 close!) ✅ Micro-Float Intact (~1.65M shares) They didn't raise because Study #7 top-line human data vs. Wegovy is dropping ANY DAY NOW, and active MTA partners like PegBio are watching closely! When multi-week steady-state bio-absorption hits, a 1.65M float doesn't just walk up... IT FLIES. 💸💊 LOCKED, LOADED, AND HOLDING FOR THE BIG READOUT! 💎🙌 $LLY $VKTX $NVO $RANI #LEXX #GLP1 #Biotech #Breakout #Bullish #DehydraTECH
1 · Reply
Hi1254
Hi1254 Aug. 18 at 11:51 AM
$RANI Chardan initiated coverage of Rani Therapeutics (RANI) with a Buy rating and $6 price target The company offers is “best-in-class” among oral delivery platforms for injectable biologics, the analyst tells investors in a research note. The firm says RaniPill has demonstrated bioavailability comparable to subcutaneous dosing, building one of the more mature in-human datasets in the space.
0 · Reply
wavw
wavw Aug. 17 at 2:51 PM
$RANI Or the warrants are exercised
0 · Reply
wavw
wavw Aug. 17 at 2:49 PM
$RANI recently they dumped 3 million shares. From 116.5 to 136.5 for 20million dump.,.and now again 3 million shares to 139.4 million.
1 · Reply
USAEquityResearch
USAEquityResearch Aug. 17 at 10:38 AM
$RANI 📊 USAEquityResearch ▼ 0.80 (-0.25%) Trend: Cautiously bearish ↘️ RSI (14): 47.2 — neutral territory MACD: turning bearish, just crossed below signal Volume: normal 📌 Key Levels Resistance: 0.90 Support: 0.69 20-MA: 0.80 | 50-MA: 0.77 Educational content only. Not financial advice.
0 · Reply
wavw
wavw Aug. 16 at 5:31 PM
$RANI tutes increased slightly to 44.39%
0 · Reply
Makingmillions192
Makingmillions192 Aug. 16 at 4:32 PM
$LEXX 🚨 MONTHLY CHART: THE MACD CROSS IS HERE! 🚨 Looking at this 1M chart, the multi-year downtrend has officially exhausted, and the structural bottom is IN. MACD Flip: MACD histogram just turned green above 0.00 with the signal lines curling upwards for a textbook bullish crossover—the exact technical setup that preceded the massive 2024 run to $60+. RSI Rebound: RSI printed a higher low near ~38 and is curling up towards 40+, showing steady momentum accumulation. Volume Baseline: Selling volume has completely dried up post-split, leaving a paper-thin float (~1.65M shares). The Spark for the Rally: This technical reversal isn't happening in a vacuum. With commercial validation rolling in (PegBio MTA + PharmaCO deals) and Human Study #7 top-line semaglutide data reading out next, fundamental execution is aligning directly with the chart. If top-line PK data beats Wegovy, this ultra-low float triggers real long-term price discovery. 🚀📈 $RANI $VKTX $LLY $NVO #GLP1
0 · Reply
wavw
wavw Aug. 14 at 9:05 PM
$RANI RA Capital disclosed 9.9% ownership. This is going to fly someday.
1 · Reply
wavw
wavw Aug. 14 at 8:23 PM
$RANI as expected…keeping below 0.80. Manipulation.
0 · Reply
Makingmillions192
Makingmillions192 Aug. 14 at 6:41 PM
$LEXX $LLY $NVO $RANI $VKTX I’m telling you boys, this is going to be a 30-40m mkt cap stock in short order.
2 · Reply